Published in Cell Death Dis on July 17, 2014
A Multicenter Phase I Study of MRX34, MicroRNA miR-RX34 Liposomal Injection | NCT01829971
Signaling by exosomal microRNAs in cancer. J Exp Clin Cancer Res (2015) 0.90
Reactivation of epigenetically silenced miR-124 reverses the epithelial-to-mesenchymal transition and inhibits invasion in endometrial cancer cells via the direct repression of IQGAP1 expression. Oncotarget (2016) 0.85
Sex differences in response to miRNA-34a therapy in mouse models of cardiac disease: identification of sex-, disease- and treatment-regulated miRNAs. J Physiol (2016) 0.83
The tumor-suppressive and potential therapeutic functions of miR-34a in epithelial carcinomas. Expert Opin Ther Targets (2015) 0.82
Evaluation of MicroRNAs Regulating Anoikis Pathways and Its Therapeutic Potential. Biomed Res Int (2015) 0.82
Investigation of Content, Stoichiometry and Transfer of miRNA from Human Neural Stem Cell Line Derived Exosomes. PLoS One (2016) 0.82
Impact of miRNAs on cardiovascular aging. J Geriatr Cardiol (2015) 0.82
RAS-MAPK pathway epigenetic activation in cancer: miRNAs in action. Oncotarget (2016) 0.81
Prolonged pemetrexed pretreatment augments persistence of cisplatin-induced DNA damage and eliminates resistant lung cancer stem-like cells associated with EMT. BMC Cancer (2016) 0.81
Fatty acid oxidation and carnitine palmitoyltransferase I: emerging therapeutic targets in cancer. Cell Death Dis (2016) 0.81
Exploring circulating micro-RNA in the neoadjuvant treatment of breast cancer. Int J Cancer (2016) 0.80
Oncogenomic portals for the visualization and analysis of genome-wide cancer data. Oncotarget (2016) 0.79
Quantitative assessment of miR34a as an independent prognostic marker in breast cancer. Br J Cancer (2014) 0.78
The Significance of miR-34a Expression in Endometrial Carcinogenesis: Correlation With Expression of p16 and Ki-67 Proteins in Endometrial Cancers. J Cancer Prev (2015) 0.78
Microrna expression signatures predict patient progression and disease outcome in pediatric embryonal central nervous system neoplasms. J Hematol Oncol (2014) 0.78
Novel miR-122 delivery system based on MS2 virus like particle surface displaying cell-penetrating peptide TAT for hepatocellular carcinoma. Oncotarget (2016) 0.78
MicroRNA-34a regulates liver regeneration and the development of liver cancer in rats by targeting Notch signaling pathway. Oncotarget (2017) 0.77
miR-34a inhibits cell proliferation in prostate cancer by downregulation of SIRT1 expression. Oncol Lett (2015) 0.77
The role of microRNAs in gallbladder cancer. Mol Clin Oncol (2016) 0.77
MiR-34a-3p alters proliferation and apoptosis of meningioma cells in vitro and is directly targeting SMAD4, FRAT1 and BCL2. Aging (Albany NY) (2017) 0.76
MiR-26a enhances the sensitivity of gastric cancer cells to cisplatin by targeting NRAS and E2F2. Saudi J Gastroenterol (2015) 0.76
The Receptor Tyrosine Kinase AXL in Cancer Progression. Cancers (Basel) (2016) 0.75
Inhibition of microRNA-34a prevents IL-1β-induced extracellular matrix degradation in nucleus pulposus by increasing GDF5 expression. Exp Biol Med (Maywood) (2016) 0.75
Downregulation of B-cell lymphoma/leukemia-2 by overexpressed microRNA 34a enhanced titanium dioxide nanoparticle-induced autophagy in BEAS-2B cells. Int J Nanomedicine (2016) 0.75
Epigenomic Regulation of Androgen Receptor Signaling: Potential Role in Prostate Cancer Therapy. Cancers (Basel) (2017) 0.75
Therapeutic microRNA-based strategies in cardiovascular disease discriminate sex and age difference. J Physiol (2016) 0.75
Expression of transforming growth factor β1 promotes cholangiocarcinoma development and progression. Cancer Lett (2016) 0.75
Computational Analysis of Specific MicroRNA Biomarkers for Noninvasive Early Cancer Detection. Biomed Res Int (2017) 0.75
MicroRNAs: New Players in Anesthetic-Induced Developmental Neurotoxicity. Pharm Anal Acta (2015) 0.75
Alzheimer's Disease: Biomarkers in the Genome, Blood, and Cerebrospinal Fluid. Front Neurol (2017) 0.75
Identification of miRNAs Potentially Involved in Bronchiolitis Obliterans Syndrome: A Computational Study. PLoS One (2016) 0.75
Targeting the MIR34C-5p-ATG4B-autophagy axis enhances the sensitivity of cervical cancer cells to pirarubicin. Autophagy (2016) 0.75
Regulation of Nuclear Receptor Nur77 by miR-124. PLoS One (2016) 0.75
Prognostic significance of MiR-34a in solid tumors: a systemic review and meta-analysis with 4030 patients. Int J Clin Exp Med (2015) 0.75
Emergence of miR-34a in radiation therapy. Crit Rev Oncol Hematol (2016) 0.75
Antitumor activity of miR-34a in peritoneal mesothelioma relies on c-MET and AXL inhibition: persistent activation of ERK and AKT signaling as a possible cytoprotective mechanism. J Hematol Oncol (2017) 0.75
MicroRNA-26a inhibits osteosarcoma cell proliferation by targeting IGF-1. Bone Res (2015) 0.75
Alternative mechanisms of miR-34a regulation in cancer. Cell Death Dis (2017) 0.75
MicroRNA-34a suppresses colorectal cancer metastasis by regulating Notch signaling. Oncol Lett (2017) 0.75
miR-3656 expression enhances the chemosensitivity of pancreatic cancer to gemcitabine through modulation of the RHOF/EMT axis. Cell Death Dis (2017) 0.75
The long non-coding RNA NEAT1 enhances epithelial-to-mesenchymal transition and chemoresistance via the miR-34a/c-Met axis in renal cell carcinoma. Oncotarget (2017) 0.75
New Tools for Molecular Therapy of Hepatocellular Carcinoma. Diseases (2015) 0.75
To Wnt or Lose: The Missing Non-Coding Linc in Colorectal Cancer. Int J Mol Sci (2017) 0.75
Multidimensional integrative analysis uncovers driver candidates and biomarkers in penile carcinoma. Sci Rep (2017) 0.75
Stem Cell-Like Properties of CK2β-down Regulated Mammary Cells. Cancers (Basel) (2017) 0.75
Reduced levels of methyltransferase DNMT2 sensitize human fibroblasts to oxidative stress and DNA damage that is accompanied by changes in proliferation-related miRNA expression. Redox Biol (2017) 0.75
Role of microRNAs in obesity and obesity-related diseases. Genes Nutr (2017) 0.75
MicroRNAs: target recognition and regulatory functions. Cell (2009) 92.17
Cancer statistics, 2008. CA Cancer J Clin (2008) 86.74
MicroRNA expression profiles classify human cancers. Nature (2005) 69.12
A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci U S A (2006) 40.09
Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A (2008) 33.65
Notch signaling: cell fate control and signal integration in development. Science (1999) 28.83
A microRNA component of the p53 tumour suppressor network. Nature (2007) 19.25
TGFbeta in Cancer. Cell (2008) 17.44
Transactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis. Mol Cell (2007) 14.58
miRNAs, cancer, and stem cell division. Cell (2005) 12.15
Neuroblastoma. Lancet (2007) 10.61
Transcriptional activation of miR-34a contributes to p53-mediated apoptosis. Mol Cell (2007) 9.51
A microRNA signature of hypoxia. Mol Cell Biol (2006) 7.24
Differential regulation of microRNAs by p53 revealed by massively parallel sequencing: miR-34a is a p53 target that induces apoptosis and G1-arrest. Cell Cycle (2007) 7.00
p53-mediated activation of miRNA34 candidate tumor-suppressor genes. Curr Biol (2007) 6.87
The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44. Nat Med (2011) 6.85
Characterization of microRNA expression levels and their biological correlates in human cancer cell lines. Cancer Res (2007) 6.57
MicroRNA-34a functions as a potential tumor suppressor by inducing apoptosis in neuroblastoma cells. Oncogene (2007) 6.55
miR-34a repression of SIRT1 regulates apoptosis. Proc Natl Acad Sci U S A (2008) 6.24
New insights into TGF-beta-Smad signalling. Trends Biochem Sci (2004) 6.13
Widespread deregulation of microRNA expression in human prostate cancer. Oncogene (2007) 5.70
Tumor-suppressive miR-34a induces senescence-like growth arrest through modulation of the E2F pathway in human colon cancer cells. Proc Natl Acad Sci U S A (2007) 5.50
Genomic profiling of microRNA and messenger RNA reveals deregulated microRNA expression in prostate cancer. Cancer Res (2008) 5.16
Chromosome 1p and 11q deletions and outcome in neuroblastoma. N Engl J Med (2005) 4.92
Hypoxia signalling through mTOR and the unfolded protein response in cancer. Nat Rev Cancer (2008) 4.50
Inactivation of miR-34a by aberrant CpG methylation in multiple types of cancer. Cell Cycle (2008) 4.35
MicroRNA-directed transcriptional gene silencing in mammalian cells. Proc Natl Acad Sci U S A (2008) 4.16
miR-328 functions as an RNA decoy to modulate hnRNP E2 regulation of mRNA translation in leukemic blasts. Cell (2010) 4.07
Genome-wide association study identifies 1p36.22 as a new susceptibility locus for hepatocellular carcinoma in chronic hepatitis B virus carriers. Nat Genet (2010) 4.01
MicroRNA miR-34 inhibits human pancreatic cancer tumor-initiating cells. PLoS One (2009) 3.66
MicroRNA-34a inhibits glioblastoma growth by targeting multiple oncogenes. Cancer Res (2009) 3.57
Bidirectional gene organization: a common architectural feature of the human genome. Cell (2002) 3.47
Yin Yang 1 is a negative regulator of p53. Cell (2004) 3.24
Development of a lung cancer therapeutic based on the tumor suppressor microRNA-34. Cancer Res (2010) 3.21
miR-34 and SNAIL form a double-negative feedback loop to regulate epithelial-mesenchymal transitions. Cell Cycle (2011) 3.15
Gain of chromosome arm 17q and adverse outcome in patients with neuroblastoma. N Engl J Med (1999) 3.03
Circulating microRNAs as blood-based markers for patients with primary and metastatic breast cancer. Breast Cancer Res (2010) 2.98
miR-34a inhibits migration and invasion by down-regulation of c-Met expression in human hepatocellular carcinoma cells. Cancer Lett (2008) 2.81
p53-independent upregulation of miR-34a during oncogene-induced senescence represses MYC. Cell Death Differ (2009) 2.80
A functional screen identifies miR-34a as a candidate neuroblastoma tumor suppressor gene. Mol Cancer Res (2008) 2.77
Systemic delivery of tumor suppressor microRNA mimics using a neutral lipid emulsion inhibits lung tumors in mice. Mol Ther (2011) 2.75
MiR-34, SIRT1 and p53: the feedback loop. Cell Cycle (2009) 2.71
miR-34a as a prognostic marker of relapse in surgically resected non-small-cell lung cancer. Carcinogenesis (2009) 2.41
Defining optimal therapy for muscle invasive bladder cancer. J Urol (2007) 2.30
Frequent downregulation of miR-34 family in human ovarian cancers. Clin Cancer Res (2010) 2.19
The quest for the 1p36 tumor suppressor. Cancer Res (2008) 1.95
Translational repression and eIF4A2 activity are critical for microRNA-mediated gene regulation. Science (2013) 1.94
microRNA regulatory network inference identifies miR-34a as a novel regulator of TGF-β signaling in glioblastoma. Cancer Discov (2012) 1.94
microRNA-34a is tumor suppressive in brain tumors and glioma stem cells. Cell Cycle (2010) 1.90
The mir-34 microRNA is required for the DNA damage response in vivo in C. elegans and in vitro in human breast cancer cells. Oncogene (2009) 1.89
Genome-wide epigenetic regulation of miRNAs in cancer. Cancer Res (2013) 1.86
MicroRNA-34a inhibits uveal melanoma cell proliferation and migration through downregulation of c-Met. Invest Ophthalmol Vis Sci (2008) 1.80
MicroRNA-34a suppresses invasion through downregulation of Notch1 and Jagged1 in cervical carcinoma and choriocarcinoma cells. Carcinogenesis (2010) 1.73
Epigenetic inactivation of the miR-34a in hematological malignancies. Carcinogenesis (2010) 1.62
Genome-wide genetic characterization of bladder cancer: a comparison of high-density single-nucleotide polymorphism arrays and PCR-based microsatellite analysis. Cancer Res (2003) 1.59
Intact p53-dependent responses in miR-34-deficient mice. PLoS Genet (2012) 1.59
Neuronal differentiation by TAp73 is mediated by microRNA-34a regulation of synaptic protein targets. Proc Natl Acad Sci U S A (2011) 1.58
MicroRNA-34 suppresses breast cancer invasion and metastasis by directly targeting Fra-1. Oncogene (2012) 1.54
miR-34a contributes to megakaryocytic differentiation of K562 cells independently of p53. Blood (2009) 1.54
Synthetic miR-34a mimics as a novel therapeutic agent for multiple myeloma: in vitro and in vivo evidence. Clin Cancer Res (2012) 1.50
Targeting epigenetic regulation of miR-34a for treatment of pancreatic cancer by inhibition of pancreatic cancer stem cells. PLoS One (2011) 1.48
MicroRNA-34a inhibits the proliferation and metastasis of osteosarcoma cells both in vitro and in vivo. PLoS One (2012) 1.45
MiR-34a attenuates paclitaxel-resistance of hormone-refractory prostate cancer PC3 cells through direct and indirect mechanisms. Prostate (2010) 1.44
Hypoxia-induced down-regulation of microRNA-34a promotes EMT by targeting the Notch signaling pathway in tubular epithelial cells. PLoS One (2012) 1.34
miR-34a predicts survival of Ewing's sarcoma patients and directly influences cell chemo-sensitivity and malignancy. J Pathol (2012) 1.34
MicroRNA-34a: a novel tumor suppressor in p53-mutant glioma cell line U251. Arch Med Res (2010) 1.30
MicroRNA-34a inhibits migration and invasion of colon cancer cells via targeting to Fra-1. Carcinogenesis (2011) 1.29
miRNA-34a is associated with docetaxel resistance in human breast cancer cells. Breast Cancer Res Treat (2011) 1.29
Transcriptional repression of miR-34 family contributes to p63-mediated cell cycle progression in epidermal cells. J Invest Dermatol (2010) 1.29
MicroRNA-34a inhibits cell proliferation by repressing mitogen-activated protein kinase kinase 1 during megakaryocytic differentiation of K562 cells. Mol Pharmacol (2010) 1.26
MicroRNA-34a is a potent tumor suppressor molecule in vivo in neuroblastoma. BMC Cancer (2011) 1.25
miR-34a and miR-15a/16 are co-regulated in non-small cell lung cancer and control cell cycle progression in a synergistic and Rb-dependent manner. Mol Cancer (2011) 1.19
Extensive promoter DNA hypermethylation and hypomethylation is associated with aberrant microRNA expression in chronic lymphocytic leukemia. Cancer Res (2012) 1.18
MiR-34a chemosensitizes bladder cancer cells to cisplatin treatment regardless of p53-Rb pathway status. Int J Cancer (2011) 1.18
Systematic proteome analysis identifies transcription factor YY1 as a direct target of miR-34a. J Proteome Res (2010) 1.17
MIRUMIR: an online tool to test microRNAs as biomarkers to predict survival in cancer using multiple clinical data sets. Cell Death Differ (2012) 1.17
MicroRNA-34a modulates c-Myc transcriptional complexes to suppress malignancy in human prostate cancer cells. PLoS One (2012) 1.17
Deletion mapping of chromosomal region 1p32-pter in primary breast cancer. Genes Chromosomes Cancer (1999) 1.15
Deregulated serum concentrations of circulating cell-free microRNAs miR-17, miR-34a, miR-155, and miR-373 in human breast cancer development and progression. Clin Chem (2013) 1.10
miR-34a confers chemosensitivity through modulation of MAGE-A and p53 in medulloblastoma. Neuro Oncol (2010) 1.10
Detection and cloning of a common region of loss of heterozygosity at chromosome 1p in breast cancer. Cancer Res (1995) 1.10
Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin. Med Oncol (2009) 1.06
MicroRNA-34a modulates MDM4 expression via a target site in the open reading frame. PLoS One (2012) 1.06
Cloning of PC3B, a novel member of the PC3/BTG/TOB family of growth inhibitory genes, highly expressed in the olfactory epithelium. Genomics (2000) 1.00
MicroRNA-34a modulates chemosensitivity of breast cancer cells to adriamycin by targeting Notch1. Arch Med Res (2012) 0.96
MicroRNA-34a suppresses cell proliferation by targeting LMTK3 in human breast cancer mcf-7 cell line. DNA Cell Biol (2013) 0.95
miR-34 cooperates with p53 in suppression of prostate cancer by joint regulation of stem cell compartment. Cell Rep (2014) 0.94
Reduced levels of miR-34a in neuroblastoma are not caused by mutations in the TP53 binding site. Genes Chromosomes Cancer (2009) 0.94
microRNA-34a sensitizes lung cancer cell lines to DDP treatment independent of p53 status. Cancer Biother Radiopharm (2012) 0.87
Detection of chromosomal alterations in bladder cancer by comparative genomic hybridization. BJU Int (2001) 0.79
Thyroid hormone inhibits TGFβ1 induced renal tubular epithelial to mesenchymal transition by increasing miR34a expression. Cell Signal (2013) 0.77